Overview and Frontier for the Development of Metallopharmaceutics

Abstract

This review introduces the development of metal-containing pharmaceutics (metallopharmaceutics) such as anticancer agents containing platinum (Pt) and ruthenium (Ru), and superoxide dismutase (SOD) mimetic, focusing on the recent topics on antidiabetic vanadium (V) and zinc (Zn) complexes as well as antioxidative copper (Cu) and Zn complexes. From the ancient ages, people used many types of inorganic compounds to treat physical disorders or diseases. Since the modern concept of chemotherapy was achieved by Paul Ehrlich, who developed the arsenic (As)-containing compound to treat syphilis in 1910, a wide variety of metallopharmaceutics have been proposed and clinically used worldwide. This review is described for the researchers who are interested in the current states for the development of metallopharmaceutics.

Synthesis and Complexation Properties of 2-Hydroxy-5-methoxyphenylphosphonic Acid (H3L1). Crystal Structure of the [Cu(H2L1)2(Н2О)2] Complex

“…With low toxicity, the analgesic effect of the complex significantly exceeds the effect of analgin. The possibility of using drugs based on complexes of transition metals, such as platinum [16,17], cobalt(II) [18], manganese(II/IV) [19], nickel(II) [20], and copper(II) [21][22][23][24][25], with organic ligands has been shown. Therefore, the synthesis of new organic compounds and OH HO H 3 L 3 SYNTHESIS AND COMPLEXATION PROPERTIES their complexes, which often exhibit higher biological activity than the initial compounds [26][27][28], is an important area of research.…”

Toxic Effects of Metallopharmaceuticals

“…This discovery opened the gate to the unexplored world of metal-based chemotherapeutic agents, which have different pharmacokinetic, pharmacodynamic and pharmacological mechanisms of action than do conventional organic drugs (2). Today, there are many successful metallopharmaceuticals that are primarily used in clinical trials not just to treat cancer but to fight a range of diseases, including parasitic and bacterial infections (3).…”

Hyphenated techniques as tools for speciation analysis of metal-based pharmaceuticals: developments and applications

“…While the use of metal compounds in medicine has a very long tradition, the extensive knowledge of the coordination and redox properties of metal ions gained more recently has facilitated the development of metal-based pharmaceuticals over the past few decades [37]. Pharmaceuticals containing metals can be divided into two main categories: therapeutic agents and diagnostic agents.…”

“…While the substitution of insulin by vanadium-or tungstenbased pharmaceuticals seems to be promising, the mechanisms of their metabolic effects in vivo are not completely understood, and so far vanadium-based drugs have been examined clinically, but these have not been approved for the market yet [37]; one vanadium-based drug that has completed phase I clinical trials and has now entered phase II clinical trials is the bis(maltolato)oxovanadium(IV) (BEOV) [118].…”